Cargando…
Machine Learning–Based Risk Assessment for Cancer Therapy–Related Cardiac Dysfunction in 4300 Longitudinal Oncology Patients
BACKGROUND: The growing awareness of cardiovascular toxicity from cancer therapies has led to the emerging field of cardio‐oncology, which centers on preventing, detecting, and treating patients with cardiac dysfunction before, during, or after cancer treatment. Early detection and prevention of can...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763760/ https://www.ncbi.nlm.nih.gov/pubmed/33241727 http://dx.doi.org/10.1161/JAHA.120.019628 |
_version_ | 1783628094839455744 |
---|---|
author | Zhou, Yadi Hou, Yuan Hussain, Muzna Brown, Sherry‐Ann Budd, Thomas Tang, W. H. Wilson Abraham, Jame Xu, Bo Shah, Chirag Moudgil, Rohit Popovic, Zoran Cho, Leslie Kanj, Mohamed Watson, Chris Griffin, Brian Chung, Mina K. Kapadia, Samir Svensson, Lars Collier, Patrick Cheng, Feixiong |
author_facet | Zhou, Yadi Hou, Yuan Hussain, Muzna Brown, Sherry‐Ann Budd, Thomas Tang, W. H. Wilson Abraham, Jame Xu, Bo Shah, Chirag Moudgil, Rohit Popovic, Zoran Cho, Leslie Kanj, Mohamed Watson, Chris Griffin, Brian Chung, Mina K. Kapadia, Samir Svensson, Lars Collier, Patrick Cheng, Feixiong |
author_sort | Zhou, Yadi |
collection | PubMed |
description | BACKGROUND: The growing awareness of cardiovascular toxicity from cancer therapies has led to the emerging field of cardio‐oncology, which centers on preventing, detecting, and treating patients with cardiac dysfunction before, during, or after cancer treatment. Early detection and prevention of cancer therapy–related cardiac dysfunction (CTRCD) play important roles in precision cardio‐oncology. METHODS AND RESULTS: This retrospective study included 4309 cancer patients between 1997 and 2018 whose laboratory tests and cardiovascular echocardiographic variables were collected from the Cleveland Clinic institutional electronic medical record database (Epic Systems). Among these patients, 1560 (36%) were diagnosed with at least 1 type of CTRCD, and 838 (19%) developed CTRCD after cancer therapy (de novo). We posited that machine learning algorithms can be implemented to predict CTRCDs in cancer patients according to clinically relevant variables. Classification models were trained and evaluated for 6 types of cardiovascular outcomes, including coronary artery disease (area under the receiver operating characteristic curve [AUROC], 0.821; 95% CI, 0.815–0.826), atrial fibrillation (AUROC, 0.787; 95% CI, 0.782–0.792), heart failure (AUROC, 0.882; 95% CI, 0.878–0.887), stroke (AUROC, 0.660; 95% CI, 0.650–0.670), myocardial infarction (AUROC, 0.807; 95% CI, 0.799–0.816), and de novo CTRCD (AUROC, 0.802; 95% CI, 0.797–0.807). Model generalizability was further confirmed using time‐split data. Model inspection revealed several clinically relevant variables significantly associated with CTRCDs, including age, hypertension, glucose levels, left ventricular ejection fraction, creatinine, and aspartate aminotransferase levels. CONCLUSIONS: This study suggests that machine learning approaches offer powerful tools for cardiac risk stratification in oncology patients by utilizing large‐scale, longitudinal patient data from healthcare systems. |
format | Online Article Text |
id | pubmed-7763760 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77637602020-12-28 Machine Learning–Based Risk Assessment for Cancer Therapy–Related Cardiac Dysfunction in 4300 Longitudinal Oncology Patients Zhou, Yadi Hou, Yuan Hussain, Muzna Brown, Sherry‐Ann Budd, Thomas Tang, W. H. Wilson Abraham, Jame Xu, Bo Shah, Chirag Moudgil, Rohit Popovic, Zoran Cho, Leslie Kanj, Mohamed Watson, Chris Griffin, Brian Chung, Mina K. Kapadia, Samir Svensson, Lars Collier, Patrick Cheng, Feixiong J Am Heart Assoc Original Research BACKGROUND: The growing awareness of cardiovascular toxicity from cancer therapies has led to the emerging field of cardio‐oncology, which centers on preventing, detecting, and treating patients with cardiac dysfunction before, during, or after cancer treatment. Early detection and prevention of cancer therapy–related cardiac dysfunction (CTRCD) play important roles in precision cardio‐oncology. METHODS AND RESULTS: This retrospective study included 4309 cancer patients between 1997 and 2018 whose laboratory tests and cardiovascular echocardiographic variables were collected from the Cleveland Clinic institutional electronic medical record database (Epic Systems). Among these patients, 1560 (36%) were diagnosed with at least 1 type of CTRCD, and 838 (19%) developed CTRCD after cancer therapy (de novo). We posited that machine learning algorithms can be implemented to predict CTRCDs in cancer patients according to clinically relevant variables. Classification models were trained and evaluated for 6 types of cardiovascular outcomes, including coronary artery disease (area under the receiver operating characteristic curve [AUROC], 0.821; 95% CI, 0.815–0.826), atrial fibrillation (AUROC, 0.787; 95% CI, 0.782–0.792), heart failure (AUROC, 0.882; 95% CI, 0.878–0.887), stroke (AUROC, 0.660; 95% CI, 0.650–0.670), myocardial infarction (AUROC, 0.807; 95% CI, 0.799–0.816), and de novo CTRCD (AUROC, 0.802; 95% CI, 0.797–0.807). Model generalizability was further confirmed using time‐split data. Model inspection revealed several clinically relevant variables significantly associated with CTRCDs, including age, hypertension, glucose levels, left ventricular ejection fraction, creatinine, and aspartate aminotransferase levels. CONCLUSIONS: This study suggests that machine learning approaches offer powerful tools for cardiac risk stratification in oncology patients by utilizing large‐scale, longitudinal patient data from healthcare systems. John Wiley and Sons Inc. 2020-11-26 /pmc/articles/PMC7763760/ /pubmed/33241727 http://dx.doi.org/10.1161/JAHA.120.019628 Text en © 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Research Zhou, Yadi Hou, Yuan Hussain, Muzna Brown, Sherry‐Ann Budd, Thomas Tang, W. H. Wilson Abraham, Jame Xu, Bo Shah, Chirag Moudgil, Rohit Popovic, Zoran Cho, Leslie Kanj, Mohamed Watson, Chris Griffin, Brian Chung, Mina K. Kapadia, Samir Svensson, Lars Collier, Patrick Cheng, Feixiong Machine Learning–Based Risk Assessment for Cancer Therapy–Related Cardiac Dysfunction in 4300 Longitudinal Oncology Patients |
title | Machine Learning–Based Risk Assessment for Cancer Therapy–Related Cardiac Dysfunction in 4300 Longitudinal Oncology Patients |
title_full | Machine Learning–Based Risk Assessment for Cancer Therapy–Related Cardiac Dysfunction in 4300 Longitudinal Oncology Patients |
title_fullStr | Machine Learning–Based Risk Assessment for Cancer Therapy–Related Cardiac Dysfunction in 4300 Longitudinal Oncology Patients |
title_full_unstemmed | Machine Learning–Based Risk Assessment for Cancer Therapy–Related Cardiac Dysfunction in 4300 Longitudinal Oncology Patients |
title_short | Machine Learning–Based Risk Assessment for Cancer Therapy–Related Cardiac Dysfunction in 4300 Longitudinal Oncology Patients |
title_sort | machine learning–based risk assessment for cancer therapy–related cardiac dysfunction in 4300 longitudinal oncology patients |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763760/ https://www.ncbi.nlm.nih.gov/pubmed/33241727 http://dx.doi.org/10.1161/JAHA.120.019628 |
work_keys_str_mv | AT zhouyadi machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients AT houyuan machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients AT hussainmuzna machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients AT brownsherryann machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients AT buddthomas machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients AT tangwhwilson machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients AT abrahamjame machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients AT xubo machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients AT shahchirag machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients AT moudgilrohit machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients AT popoviczoran machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients AT choleslie machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients AT kanjmohamed machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients AT watsonchris machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients AT griffinbrian machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients AT chungminak machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients AT kapadiasamir machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients AT svenssonlars machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients AT collierpatrick machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients AT chengfeixiong machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients |